慢性C 型肝炎病毒(Hepatitis C virus, HCV)在台灣東部地區感染與治療之現況

The Study for the Treatment and Infection of Chronic hepatitis C Virus (Hepatitis C virus, HCV) in the Eastern Part of Taiwan's

全球估計約有一億八千多萬人口（約佔全世界人口的3%）遭受HCV的感染，每年也增加約3-4百萬新的感染案。HCV其傳染途徑主要以血液及體液接觸傳染為主，如：輸血傳染、注射毒品、刺青及性行為等。HCV感染會導致慢性肝臟疾病包含肝纖維化、晚期的肝硬化及肝癌(hepatocellularcarcinoma, HCC)。所以，HCV感染的預防控制及積極治療成效上，是需要努力克服的一大挑戰。所以我們就東部近年來臨床上感染HCV的病人做淺略的探討及分析，進一步初步了解目前台灣東部HCV感染的現況及其治療的成效之相關性。我們將以回溯性方式收集於2010年至2014年已治療結束之C型肝炎患者其治療期間有關工作型態，飲食習慣等可能和慢性肝病有關的資訊，包括:病歷記載、檢驗數據、影像學檢查或其他醫療相關文件及資料。由結果發現東部地區發現HCV感染人數有明顯的下降，其基因型與台灣其他地區相似仍以genotype 1b最多，其次為genotype 2a。而且HCV成功治療約占69.58%，期待較低副作用及較強的病毒抑制劑能帶給HCV的病人更好療效。

Worldwide is estimated that about one hundred million more than eighty million people (about 3% of the world's population) suffer from HCV infection also increased by approximately 3-4 million per year of new cases of infection [3,4]. HCV its spread by blood and body fluids contagious based, such as: blood transfusion, injecting drugs, tattoos and sexual behavior. HCV infection can lead to chronic liver disease including liver fibrosis, cirrhosis and liver cancer late (hepatocellular carcinoma, HCC).We arrived nearly three eastern bed hospital patients infected with HCV do a little shallow discussion and analysis, and further preliminary understanding of current HCV infection in eastern Taiwan and the effectiveness of the treatment status of the correlation. We collected retrospectively from 2010 to 2013 at the end of treatment of the hepatitis C patients during their treatment related work patterns, eating habits and chronic liver disease may be related information, including: medical records, laboratory data, imaging examination or other medical-related documents and information, providing clinicians an academic scientific research purposes. The results showed that the eastern region by the number of people infected with HCV found a significant decline. HCV genotype similar to other areas in Taiwan is still genotype 1b, followed by the genotype 2a. Successful treatment of HCV and accounted for 69.58%, expect less side effects and a strong viral inhibitors can bring better efficacy in patients with HCV.